{"schema_version":"1.0","type":"article","title":"鬼剃頭新藥，先別封神","url":"https://drugnews.com.tw/articles/2026-08-02-bempikibart-alopecia-areata.html","markdown_url":"https://drugnews.com.tw/articles/2026-08-02-bempikibart-alopecia-areata.md","lang":"zh-Hant","date":"2026-08-02","publish_at":"2026-08-02T08:00:00+08:00","updated_at":"2026-08-02","category":"商業分析系列","topic":"商業分析系列","tags":["斑禿","鬼剃頭","Bempikibart","Q32 Bio","QTTB","IL-7Rα","JAK 抑制劑","SALT","生技股","新藥研發"],"summary":"33 人、單臂、開放標籤的 Phase 2a 資料讓 Q32 Bio 股價近乎翻倍；真正的問題是療效能否重現、停藥後能否維持，以及安全性是否足以改變 JAK 抑制劑的臨床位置。","key_points":[],"facts":[],"sections":["01｜先看清楚：SALT 代表什麼？","02｜40% 很醒目，但分母只有 25","03｜非 JAK 為什麼讓市場這麼興奮？","04｜「停藥後還在長」目前只是一個問號","05｜股價近乎翻倍以後，真正的考試才開始","06｜斑禿治療的下一輪競爭","07｜台灣讀者的產業座標","08｜結論：先把「值得驗證」和「已經證明」分開","參考資料","免責聲明"],"references":[{"title":"以下均為一級來源或官方試驗登錄。查證截止：2026-07-19。","source":"","date":"","url":""},{"title":"Q32 Bio，SIGNAL-AA Part B 36 週頂線結果：","source":"","date":"","url":"https://ir.q32bio.com/news-releases/news-release-details/q32-bio-announces-positive-36-week-topline-results-part-b-signal"},{"title":"ClinicalTrials.gov，SIGNAL-AA（NCT06018428）：","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT06018428"},{"title":"Q32 Bio，2 億美元公開發行定價：","source":"","date":"","url":"https://ir.q32bio.com/news-releases/news-release-details/q32-bio-announces-pricing-200-million-public-offering-common/"},{"title":"Q32 Bio SEC filing：","source":"","date":"","url":"https://ir.q32bio.com/node/10981/html"},{"title":"AbbVie，upadacitinib 斑禿適應症 FDA 申請：","source":"","date":"","url":"https://news.abbvie.com/2026-04-28-AbbVie-Submits-Application-to-FDA-for-Upadacitinib-RINVOQ-R-for-Adults-and-Adolescents-with-Severe-Alopecia-Areata"},{"title":"Nektar，REZOLVE-AA 52 週資料與開發期別：","source":"","date":"","url":"https://ir.nektar.com/news-releases/news-release-details/52-week-topline-results-16-week-blinded-treatment-extension"},{"title":"Nasdaq，QTTB 歷史價格：","source":"","date":"","url":"https://www.nasdaq.com/market-activity/stocks/qttb/historical"}],"images":[{"alt":"33 人讓股價近乎翻倍，但單臂 Phase 2a 資料仍只是進入下一階段的門票","url":"https://drugnews.com.tw/assets/articles/bempikibart-alopecia-areata/figure-01.png"},{"alt":"同樣 10 名患者達到 SALT 不超過 20，mITT 與 ITT 分母會得出不同百分比","url":"https://drugnews.com.tw/assets/articles/bempikibart-alopecia-areata/figure-02.png"},{"alt":"33 人研究沒有觀察到嚴重安全事件，不代表擴大暴露後不會出現低頻重要風險","url":"https://drugnews.com.tw/assets/articles/bempikibart-alopecia-areata/figure-03.png"},{"alt":"Bempikibart 下一場考試包括第 52 週、對照設計、療效重現與長期安全","url":"https://drugnews.com.tw/assets/articles/bempikibart-alopecia-areata/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/bempikibart-alopecia-areata/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-08-02）。鬼剃頭新藥，先別封神。https://drugnews.com.tw/articles/2026-08-02-bempikibart-alopecia-areata.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-08-02-bempikibart-alopecia-areata-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}